磷酸二酯酶Ⅲ抑制剂在肺心病急性加重期的应用

目的:评价磷酸二酯酶Ⅲ抑制剂(米力农)在慢性肺源性心脏病急性加重期控制心衰的临床应用价值和安全性。方法:将本院52例COPD合并肺源性心脏病急性加重期的病人随机分为两组,治疗组(n=35)采用米力农控制心力衰竭,对照组(n=17):用强心甙控制心力衰竭,其他治疗两组基本相似。结果:与同组治疗前相比,米力农降低舒张压较明显,强心甙明显减慢心率。在改善心功能方面,治疗组显效17例,有效15例,总有效率为91.4％,对照组显效9例,有效7例,总有效率为94.1％,两组无显著差异(P>0.05)。结论:米力农用于治疗慢性肺源性心脏病急性加重期心力衰竭疗效肯定,不良反应较少,无洋地黄中毒的潜在危险,值得推荐。

The Clinical Application of Milrinone in Chronic Cor Pulmonale Exacerbation.

Objective: To evaluate the clinical efficacy and safety of milrinone as a cardiac stimulant in chronic cor pulmonale exacerbation.Methods: 52 patients who suffered from COPD with chronic cor pulmonale were collected. All patients in cor pulmonale exacerbation were divided into two groups. The experimental group(rc = 35) was treated with milrinone to control heart failure.The control group(n = 17) was treated with digitalis to control heart failure.Other treatments were similar. Re-sults: Compared with the pretreatment, Milrinone reduced diastolic pressure significantly. Digitalis decreased heart rates signif -icantly. In respect of improving the heart pump failure,the total effective rate of two groups were 91. 4% and 94.1% respec-tively.There was no statistical significance between two groups(P>0.05).Conclusion; Milrinone is an effective drug in con-trolling heart failure of patients in chronic cor pulmonale exacerbation. The side effects of Milrinone are mild and there is no potential risk of digitalis toxicity.